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Machado–Joseph disease (MJD) is the most common dominant inherited ataxia
worldwide, caused by an unstable CAG trinucleotide expansion mutation within the SCA3
gene resulting in an expanded polyglutamine tract within the ataxin-3 protein. Ataxin-3 func-
tions as a deubiquitinating enzyme (DUB), within the Ub system and whilst many DUBs are
known to partner with and deubiquitinate specific E3-Ub ligases, ataxin-3 had no identified
E3 partner until recent studies implicated parkin and CHIP, two neuroprotective E3 ligases.
MJD often presents with symptoms of Parkinson disease (PD), which led to identifica-
tion of parkin as a novel E3-Ub ligase whose activity was regulated by ataxin-3-mediated
deubiquitination. Findings from these studies also revealed an unexpected convergence
upon the E2-Ub-conjugating enzyme in the regulation of an E3/DUBenzyme pair. More-
over, mutant but not wild-type ataxin-3 promotes the clearance of parkin via the autophagy
pathway, raising the intriguing possibility that increased turnover of parkin may contribute
to the pathogenesis of MJD and help explain some of the Parkinsonian features in MJD. In
addition to parkin, theU -box E3 ligase CHIP, a neuroprotective E3 implicated in protein qual-
ity control, was identified as a second E3 partner of ataxin-3, with ataxin-3 regulating the
ability of CHIP to ubiquitinate itself. Indeed, ataxin-3 not only deubiquitinated CHIP, but also
trimmed Ub conjugates on CHIP substrates, thereby regulating the length of Ub chains.
Interestingly, when expanded ataxin-3 was present, CHIP levels were also reduced in the
brains of MJD transgenic mice, raising the possibility that loss of one or both E3 partners
may be a contributing factor in the pathogenesis of SCA3. In this review we discuss the
implications from these studies and describe the importance of these findings in helping
us understand the molecular processes involved in SCA3 and other neurodegenerative
disorders.
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ATAXIN-3: A DEUBIQUITINATING ENZYME
Machado–Joseph disease (MJD) is one of nine polyQ disorders
caused by a CAG expansion mutation within the SCA3/MJD1
gene that encodes the ataxin-3 protein (Kawaguchi et al., 1994).
Expansion of its polyglutamine (polyQ) tract is believed to lead
to a toxic gain of function, with calpain-dependent proteolysis of
the mutant ataxin-3 generating expanded polyQ fragments and
ultimately insoluble aggregates (Paulson et al., 1997; Fujigasaki
et al., 2000; Chai et al., 2001; Koch et al., 2011). However, despite
the shared mechanisms between these disorders, differences exist
at both the clinical and neuropathological level, which cannot
be accounted for by the polyQ expansion alone. Indeed, under-
standing the normal function of ataxin-3 can help explain why
expansion of the polyQ tract in ataxin-3 is causing some of the
specific features associated with MJD.
A well-characterized function of ataxin-3 is its role in the
ubiquitin (Ub)-proteasome (UPS) system (Burnett et al., 2003;
Doss-Pepe et al., 2003; Scheel et al., 2003) as a deubiquitinating
enzyme (DUB). As a DUB, ataxin-3 possesses two distinct features
for it to function in the UPS. The first is its N-terminal Josephin
domain, that confers ataxin-3 with a cysteine protease activity for
hydrolyzing Ub linkages (Scheel et al., 2003; Nicastro et al., 2005).
The second critical feature are its three Ub-interacting motifs
(UIMs), through which ataxin-3 binds Ub conjugates and ubiq-
uitinated proteins (Burnett et al., 2003; Donaldson et al., 2003),
bringing it into proximity to trim or edit specific linkages within
these Ub conjugates (Burnett and Pittman, 2005; Winborn et al.,
2008; Scaglione et al., 2011) (Figure 1A). Thus, ataxin-3 can bind
to and deubiquitinate Ub conjugates, leading us to ask, what are
the ubiquitinated substrates ataxin-3 acts upon. Moreover, what
are the functional consequences of ataxin-3-mediated deubiqui-
tination and does the expansion of the polyQ tract in MJD affect
this normal function?
Ataxin-3 is one of 98 known DUBs, that function to deubiq-
uitinate a wide range of substrates, that includes many E3-Ub
ligases. E3s function within the UPS to mediate the covalent
attachment of Ub onto lysine residues within target proteins
(Shimura et al., 2000) thereby influencing many different cellu-
lar pathways. Typically, DUBs oppose this activity of the E3’s by
mediating the removal of Ub from target proteins. However, many
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FIGURE 1 | (A) Schematic representation of ataxin-3. Ataxin-3 contains an
N-terminal Josephin domain, and three Ub-interacting motifs (UIMs) that
flank a polyQ tract of variable length. In normal individuals, this tract can be
anywhere from 10 to 51Q. In individuals with MJD, this tract has expanded
to now contain >51Q. (B) Schematic representation of the interaction
between ataxin-3 and CHIP. (1) CHIP contains an N-terminal
tetratricopeptide repeat (TPR) domain and a C-terminal U -Box domain that
confers CHIP with E3-Ub ligase activity. CHIP monoubiquitinates itself at
lysine 2 (K2), which in turn facilitates the interaction between CHIP and
ataxin-3. CHIP and ataxin-3 also interact directly although the nature of this
interaction has yet to be characterized. (C) Schematic representation of the
interaction between ataxin-3 and parkin. Parkin interacts directly with
ataxin-3 via its N-terminal Ub-like domain (Ubl) that binds to the UIMs of
ataxin-3, and through its inbetweenring-RING2 (IBR-RING2) domain binding
to the Josephin domain of ataxin-3.
E3s regulate their own stability and ability by ubiquitinating them-
selves. Often, these Ub conjugates target the E3 to the proteasome
for degradation (Kao et al., 2000), although destruction of the
E3 can be delayed or prevented by one or more DUBs remov-
ing these conjugates (Nathan et al., 2008). Paradoxically, DUBs
can sometimes promote the degradation of an E3 by removing
non-canonical Ub conjugates, which are protecting the E3 from
degradation, enabling another E3 to ubiquitinate the E3 in ques-
tion, thereby promoting its degradation (de Bie et al., 2010). To
complicate matters, certain DUBs have been demonstrated to reg-
ulate the activity of E3s via deubiquitination (Scaglione et al.,
2011). Given that DUBs often deubiquitinate multiple E3s (Daviet
and Colland, 2008; Nathan et al., 2008), and since the number
of E3s far outnumber DUBs, it is likely that ataxin-3-mediated
deubiquitination is regulating the function of multiple E3s.
ATAXIN-3 AND CHIP
Early studies hinted that the U -box E3-Ub ligase CHIP might
be one such E3 that interacts with ataxin-3. Consistent with this
notion, CHIP was first observed to ubiquitinate the expanded
form of ataxin-3, thereby directing it for degradation (Jana et al.,
2005) In later studies, ataxin-3 was demonstrated to deubiqui-
tinate CHIP, making CHIP the first E3 identified that could be
deubiquitinated by ataxin-3 (Winborn et al., 2008). Conversely,
CHIP ubiquitinates wild-type ataxin-3, which in turn enhances
the overall deubiquitinating activity of ataxin-3 (Todi et al., 2010).
Thus, CHIP and ataxin-3 interact and regulate the activity of each
other. Of note, unlike other E3: DUB partners in which levels
of the E3 are regulated by deubiquitination, changes in ataxin-3
levels do not have any effect on CHIP levels, making it unlikely
that ataxin-3-mediated deubiquitination regulates degradation of
CHIP (Scaglione et al., 2011). Rather, ataxin-3 appears to regu-
late the E3 ligase activity of CHIP in the protein quality control
pathway.
Typically, E3-Ub ligases mediate the attachment of Ub moieties
onto themselves, and CHIP is no exception. Through its inter-
action with the E2-conjugating enzyme Ube2W, CHIP robustly
monoubiquitinates itself on lysine 2 (K2), which in turn enhances
its overall E3 ligase activity (Scaglione et al., 2011). When CHIP
was unable to self-ubiquitinate, its ability to ubiquitinate a variety
of substrates was impaired. Intriguingly, monoubiquitination of
CHIP appears to enhance the interaction between ataxin-3 and
CHIP, and when bound, ataxin-3 can now deubiquitinate CHIP
(Figure 1B). Evidence further supporting this notion that the abil-
ity of ataxin-3 to deubiquitinate CHIP is coupled to the ligase
activity of CHIP, came from assays in which ataxin-3-mediated
deubiquitination of CHIP did not occur until after poly-Ub con-
jugates on substrate proteins had attained a certain length. Once
this occurred, ataxin-3 could now deubiquitinate both CHIP and
its substrates, trimming the Ub conjugates at the distal ends. This
prevented these conjugates from being extended further (Scaglione
et al., 2011). Taken together, ataxin-3 opposes the activity of CHIP
by deubiquitinating CHIP and by editing the Ub conjugates that
it forms on different substrates.
As ataxin-3 tightly regulates the ability of CHIP to ubiquitinate
itself and its substrates, why then might this ability of ataxin-3
to edit Ub conjugates be important? With CHIP, ataxin-3 ensures
that the Ub conjugates are the appropriate length to efficiently
target substrates for proteasomal degradation. Furthermore, by
inactivating CHIP via deubiquitination, ataxin-3 tightly regulate
the activity of CHIP within the protein quality control pathway,
ensuring that it can only ubiquitinate misfolded proteins targeted
for degradation. However, if CHIP is unable to remove these pro-
teins, resulting in an accumulation of misfolded proteins, ataxin-3
again utilizes its editing activity to help sequester these proteins
into structures termed aggresomes, thereby mitigating the effects
of misfolded protein toxicity within the cell (Ouyang et al., 2012;
Wang et al., 2012). In this pathway, ataxin-3 edits Ub conjugates on
misfolded proteins to generate free Ub C termini that are recog-
nized by HDAC6 and subsequently sequestrated to the aggresomes
Frontiers in Neurology | Neurodegeneration May 2013 | Volume 4 | Article 46 | 2
Durcan and Fon E3 partners of ataxin-3
(Ouyang et al., 2012). Thus, as an editor of Ub conjugates, ataxin-
3 not only tightly regulates CHIP in the protein quality control
pathway, but acts independently of CHIP to sequester misfolded
proteins into aggresomes, providing the cell with multiple layers
of protection from misfolded protein toxicity.
ATAXIN-3-MEDIATED REGULATION OF PARKIN ACTIVITY
Individual DUBs often deubiquitinate and regulate the activity
of multiple E3s (Daviet and Colland, 2008; Nathan et al., 2008),
making it likely that ataxin-3 can deubiquitinate other E3s. Inter-
estingly, MJD can present with clinical and neuropathological
symptoms of Parkinson disease (PD), and this raises the possi-
bility that an interaction between ataxin-3 and a PD-associated
protein could be involved in MJD (Gwinn-Hardy et al., 2001;
Bettencourt et al., 2011). Similar to CHIP, the PD-associated E3
parkin was demonstrated to ubiquitinate and facilitate the clear-
ance of an expanded ataxin-3 fragment (Tsai et al., 2003). Parkin
interacts directly with distinct UIMs in ataxin-3 via its N-terminal
Ub-like domain (Ublparkin) (Figure 1C) (Durcan et al., 2011).
Through its interaction with parkin, ataxin-3 regulates the ability
of parkin to ubiquitinate itself, with ataxin-3 reducing parkin self-
ubiquitination both in cells and in vitro. Interestingly, although
ataxin-3 deubiquitinates parkin, parkin is unable to ubiquitinate
ataxin-3 (Durcan et al., 2011, 2012). Finally, ataxin-3-mediated
deubiquitination appears to only regulate parkin activity, as the
presence or absence of wild-type ataxin-3 had no effect on overall
parkin levels (Durcan et al., 2011).
With CHIP, ataxin-3 could trim/edit Ub chains after they had
formed on substrates and was able to catalyze the removal of
mono-Ub off CHIP (Scaglione et al., 2011). With parkin, ataxin-3
was unable to remove individual Ub moieties or preformed Ub
chains after they had formed, suggesting that ataxin-3 was deu-
biquitinating parkin through a more unconventional mechanism
(Durcan et al., 2012). One clue came from in vitro assays in which
ataxin-3 regulates the formation of Ub conjugates on parkin, only
when parkin was actively ubiquitinating. These findings suggest
that ataxin-3 actively opposes the ligation of Ub on parkin, thereby
impeding the ability of parkin to self-ubiquitinate.
Recently, parkin has been demonstrated to function as a
RING/HECT hybrid, with the charged E2-Ub directly transfer-
ring the Ub onto cysteine 431 of parkin (Wenzel et al., 2011;
Lazarou et al., 2013). This results in the formation of a parkin-
Ub thioester intermediate complex, prior to parkin ligating the
Ub onto itself (Figure 2A). Given that ataxin-3 and parkin inter-
act directly, as demonstrated from in vitro binding data, how then
is ataxin-3 interfering with the ability of parkin to ubiquitinate
itself. Through its cysteine at residue 14, ataxin-3 alone can interact
directly with the E2s used by parkin to self-ubiquitinate (Durcan
et al., 2012). Remarkably, when the cysteine was mutated to a ser-
ine, this interaction was now abolished. When parkin was present,
ataxin-3 could not only interact with both parkin and the E2, but
it could also promote the transfer of the Ub away from parkin and
onto itself. Such E3-like activity is not unprecedented for a DUB,
with both UCH-L1 and A20 possessing E3 and DUB activities (Liu
et al., 2002; Wertz et al., 2004), although further work is required
to ascertain how ataxin-3 might act as an E3-like DUB. From these
findings, we propose a model whereby ataxin-3 binds directly to
FIGURE 2 | (A) Model representation of how ataxin-3-mediated
deubiquitination regulates parkin self-ubiquitination. When parkin
ubiquitinates itself, the charged E2-Ub thioester transfers the Ub onto
C431 in parkin to form a transient parkin-Ub thioester complex (1).
Parkin now transfers this Ub onto one of its own lysines generating an
isopeptide linkage (2). Following the transfer of Ub onto itself, parkin is
now free to receive a new Ub and this continues the cycle of parkin
self-ubiquitination (3). When ataxin-3 is present, we propose that
ataxin-3, through its interaction with the IBR-RING2 domain of parkin,
blocks the C431 residue, impeding parkin from forming a parkin-Ub
thioester. Instead, ataxin-3 now interacts with the E2, directing the
transfer of Ub onto a lysine within ataxin-3 (4). This isopeptide linkage is
transient as ataxin-3 can catalyze its removal (5) (unpublished data),
allowing ataxin-3 to repeat this cycle of
self-ubiquitination/deubiquitination, thereby reducing the ability of parkin
to ubiquitinate itself (6 and 7). (B) Proposed model for how the
expanded ataxin-3 can promote the autophagic clearance of parkin. In
the presence of calcium, calpains cleave full-length ataxin-3, generating
fragments containing the expanded polyQ tract (1). These fragments can
associate with mitochondria (2), causing mitochondrial damage, parkin
recruitment (3), and ultimately parkin-mediated clearance of itself and
the mitochondria via the autophagy pathway (6). Alternatively, these
expanded polyQ fragments also have a propensity to aggregate (4),
recruiting parkin and CHIP (5), which now act to direct these aggregates
and themselves for autophagic clearance (6).
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parkin, blocking the E2 from transferring the Ub onto C431 in
parkin. As a result, the E2 now transfers the Ub onto ataxin-3
and away from parkin, thereby impeding the activity of parkin to
ubiquitinate itself.
MJD, MUTANT ATAXIN-3, AND ITS E3 PARTNERS
From these studies, it is clear that ataxin-3 is involved in tightly
regulating the activity of two E3s that function to maintain nor-
mal cellular homeostasis. Strikingly, in mouse models of MJD,
levels of both CHIP and parkin are significantly reduced when
the polyQ tract becomes expanded over 51 glutamines, thereby
disrupting the normal cellular homeostasis and promoting neu-
ronal cell loss. Thus, when mutated, ataxin-3 now promotes the
destruction of two quality control E3s. Yet, why does the presence
of an expanded polyQ tract in ataxin-3 enhance the clearance of
both E3s, is this effect dependent on the DUB ability of ataxin-
3 or is it caused by the expanded polyQ tract. In the case of
CHIP, expansion of the polyQ tract increases the binding between
CHIP and ataxin-3, leading to a reduction in CHIP levels in the
brains of MJD transgenic mice (Scaglione et al., 2011). One pos-
sibility is that the increased affinity of mutant ataxin-3 for CHIP
somehow alters their functional relationship, inadvertently caus-
ing CHIP to be directed for degradation. Although it is unclear why
CHIP is degraded, a reduction in CHIP levels will have an adverse
effect on the protein quality control pathway. Consequently, an
accumulation of misfolded neurotoxic proteins can be a key con-
tributing factor in the progressive loss of neurons associated with
MJD.
Intriguingly, the presence of the mutant ataxin-3 also causes
a reduction in parkin levels in the brains of MJD transgenic
mice. These findings were further confirmed and extended in
cells, with the presence of the expanded form of ataxin-3 promot-
ing clearance of parkin through the autophagy pathway (Durcan
et al., 2011). However the mechanism remains unclear. Recent
studies have highlighted the role of K27-, K29-, and K63-linked
Ub in directing proteins for degradation via the lysosomal and
autophagy pathways. Interestingly, parkin assembles Ub conju-
gates on itself preferentially via these linkages and when compared
to wild-type ataxin-3, the polyQ expanded mutant ataxin-3 was
more efficient at removing K27- and K29-linked Ub conjugates
from parkin. One possibility is that these K27- and K29-linked
Ub conjugates protect parkin from autophagic degradation, and
their preferential removal enhances parkin turnover via autophagy
(Durcan and Fon, 2011).
Alternatively, and a more likely scenario, is that the effect of
expanded ataxin-3 on parkin occurs independently of its cat-
alytic activity and is a direct effect of the expanded polyQ tract
(Figure 2B). Autophagy has been implicated in clearing mutant
polyQ protein aggregates in several models of polyQ expan-
sion disorders, including MJD. In this scenario, fragments of the
expanded polyQ tract generated from the mutant ataxin-3 cause
aggregates to form. By interacting with these inclusions and direct-
ing them for destruction, CHIP and parkin may in a sense “just
go along for the ride,” ultimately resulting in both their clearance
along with the aggregates. Thus, over time, extensive clearance of
these aggregates can cause levels of CHIP and parkin to dimin-
ish. We also cannot exclude a second possibility, that parkin and
CHIP are actively involved in the autophagic process, as has been
reported for the recently identified role for parkin in target-
ing damaged mitochondria for autophagic removal (mitophagy)
(Narendra et al., 2008). Interestingly, mitochondrial abnormalities
have been observed in models of polyQ disorders, including MJD
(Ranganathan et al., 2009; Yu et al., 2009; Kazachkova et al., 2012;
Laco et al., 2012; Reddy and Shirendeb, 2012). Moreover, polyQ
fragments generated from mutant ataxin-3 can interact with and
damage mitochondria (Pozzi et al., 2008; Sugiura et al., 2011;
Kazachkova et al., 2012). This in turn can now potentially promote
the mitochondria recruitment of parkin, triggering the autophagic
clearance of parkin-bound mitochondria (Chai et al., 2001; Koch
et al., 2011). Taken together, ataxin-3 forms partnerships with two
E3s that are essential for maintaining normal cellular homeostasis.
In MJD, these partnership are not only disrupted, but the presence
of the expanded ataxin-3 now promotes clearance of both parkin
and CHIP, which over time can have deleterious consequences on
neurons in MJD and PD.
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